Get Level 2

Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Genedrive Share Price
  4. Genedrive Share Regulatory News
  5. Notifiable Interest

Pin to quick picksGenedrive Regulatory News (GDR)

Genedrive Information

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Notifiable Interest

2 Nov 2007 08:56

EpiStem Holdings plc02 November 2007 EpiStem Holdings plc 2 November 2007 EpiStem Holdings plc (the "Company") was informed on 31 October by IS PartnersInvestment Solutions AG as advisors to the Helium Special Situations Fund (the"Fund"), that the Fund has increased its shareholdings in the Company from420,600 to 513,100 ordinary shares. This increase came through several recentpurchases. As a consequence the Fund now holds 7.85% of the issued share capitalof the Company, up from 6.43% previously. Contacts: EpiStem Holdings Plc: Matthew Walls (CEO)Tel: 0161 606 7263John Rylands (Financial Director and Company Secretary)Tel: 0161 606 7258 Landsbanki Securities (UK) Limited: Thilo Hoffmann/Simon BrownTel: 020 7426 9000 MC Bio-Communications Limited: Mike WortTel: 020 7744 7711 This information is provided by RNS The company news service from the London Stock Exchange
12345678910
Date   Source Headline
6th Oct 20257:00 amRNSFurther re Equity Financing
2nd Oct 20256:18 pmRNSHolding(s) in Company
1st Oct 202512:31 pmRNSHolding(s) in Company
1st Oct 202512:30 pmRNSHolding(s) in Company
30th Sep 20259:52 amRNSHolding(s) in Company
29th Sep 20255:03 pmRNSHolding(s) in Company
29th Sep 20253:00 pmRNSPublication of Circular and Notice of GM
29th Sep 20257:00 amRNSResult of Retail Offer
24th Sep 20257:00 amRNSCompletion of Placing
23rd Sep 20255:03 pmRNSProposed Retail Offer
23rd Sep 20254:59 pmRNSProposed Placing to raise a minimum of £3 million
23rd Sep 20259:00 amRNSHolding(s) in Company
23rd Sep 20259:00 amRNSHolding(s) in Company
15th Sep 20254:24 pmRNSResult of General Meeting
10th Sep 20254:15 pmRNSHolding(s) in Company
10th Sep 20254:15 pmRNSHolding(s) in Company
29th Aug 202512:00 pmRNSProposed Share Capital Reorganisation & GM
21st Aug 20257:00 amRNSScotland’s Public Health Minister visit
14th Aug 202510:35 amRNSComment re: Share Price Movement
11th Aug 20257:00 amRNSTrading update
30th May 20257:00 amRNSBlock Listing Returns
30th May 20257:00 amRNSCE-certification
13th May 20257:00 amRNSCYP2C19-ID Kit used to support expansion
2nd May 20251:30 pmRNSCYP2C19 ID Kit CE-IVD certification update
2nd Apr 20257:01 amRNSAdditional grant funding under DEVOTE programme
2nd Apr 20257:00 amRNSReceipt of R&D tax credit
1st Apr 20257:00 amRNSResult of RetailBook Offer
27th Mar 20253:30 pmRNSRetailBook Offer
27th Mar 20253:29 pmRNSHalf-year Report
27th Mar 20253:28 pmRNSEquity Fundraise
17th Mar 202511:04 amRNSScottish Government testing programme investment
14th Mar 20257:00 amRNSCYP2C19-ID Kit adopted for routine clinical use
30th Dec 202411:54 amRNSResult of AGM
27th Dec 20247:00 amRNSGenedrive® CYP2C19-ID Kit performance published
20th Dec 202412:16 pmRNSGrant of Options
20th Dec 202412:12 pmRNSDirector/PDMR Shareholding
5th Dec 20243:00 pmRNSPosting of annual report and notice of AGM
29th Nov 20241:00 pmRNSBlock listing returns
29th Nov 20247:00 amRNSFinal Results
22nd Nov 20247:00 amRNSNotice of Results
21st Nov 202411:06 amRNSNIHR and OLS Funding Package
4th Nov 20241:29 pmRNSScottish Health Technology Group publications
21st Oct 20243:22 pmRNSDirector Declaration
15th Aug 202410:39 amRNSDirector/PDMR Shareholding
12th Aug 20247:00 amRNSFirst UK commercial sales of the CYP2C19-ID Kit
6th Aug 20247:00 amRNSDirectorate Change
31st Jul 20247:00 amRNSNICE recommends CYP2C19-ID Kit in final guidance
15th Jul 20247:00 amRNSBreakthrough Device Designation from the U.S. FDA
27th Jun 20249:28 amRNSShort extension to NICE publication date
25th Jun 20247:00 amRNSHolding(s) in Company
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
AVM
AVM.L
LSE
0.00%
LSEG
London Stock Exchange
LSE
1.06%
IGV
Inc&gwth Vct
LSE
0.00%
JPB
JPB.L
LSE
0.00%
BUT
Brunner Inv.tst
LSE
0.67%
Trending
GST
GSTechnologies
LSE
0.00%
MPL
Mercantile Ports & Logistics
LSE
-18.42%
EZJ
easyJet
LSE
-4.05%
KEFI
Kefi Gold & Copper
LSE
0.00%
EME
Empyrean
LSE
41.18%